Trader consensus on Polymarket reflects a 66.5% implied probability against Sam Altman receiving OpenAI equity by June 30, driven by explosive revelations in the ongoing Elon Musk versus OpenAI trial, now in its second week as of late April 2026. Testimonies from former board member Helen Toner and Wall Street Journal reporting exposed Altman's undisclosed control of the OpenAI Startup Fund while he publicly claimed zero equity stakes to Congress and investors, reigniting governance concerns from his 2023 ouster and rehiring. Amid aggressive 2026 IPO plans flagged as risky by CFO Sarah Friar, and persistent conflicts like pushing OpenAI investments into his personal ventures (Helion fusion, Stoke Space), the board faces heightened legal and reputational barriers to granting equity soon. Trial outcome and any mandated nonprofit remedies could further delay resolution.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedTaking equity is defined as Sam Altman acquiring or being granted shares, stock options, or any other form of ownership interest in OpenAI.
Any pre-existing interest held through Y Combinator's investment fund or other indirect holdings made prior to Altman becoming full-time at OpenAI will not count toward this market's resolution.
The resolution source for this market will be a consensus of credible reporting.
Market Opened: Nov 12, 2025, 5:14 PM ET
Resolver
0x65070BE91...Taking equity is defined as Sam Altman acquiring or being granted shares, stock options, or any other form of ownership interest in OpenAI.
Any pre-existing interest held through Y Combinator's investment fund or other indirect holdings made prior to Altman becoming full-time at OpenAI will not count toward this market's resolution.
The resolution source for this market will be a consensus of credible reporting.
Resolver
0x65070BE91...Trader consensus on Polymarket reflects a 66.5% implied probability against Sam Altman receiving OpenAI equity by June 30, driven by explosive revelations in the ongoing Elon Musk versus OpenAI trial, now in its second week as of late April 2026. Testimonies from former board member Helen Toner and Wall Street Journal reporting exposed Altman's undisclosed control of the OpenAI Startup Fund while he publicly claimed zero equity stakes to Congress and investors, reigniting governance concerns from his 2023 ouster and rehiring. Amid aggressive 2026 IPO plans flagged as risky by CFO Sarah Friar, and persistent conflicts like pushing OpenAI investments into his personal ventures (Helion fusion, Stoke Space), the board faces heightened legal and reputational barriers to granting equity soon. Trial outcome and any mandated nonprofit remedies could further delay resolution.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions